Screener
Jade Biosciences JBIO Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Jade Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:27 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212088
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accrued expenses and other current liabilities | 5,772 | (1,948) |
| Related party accrued expenses and other current liabilities | (4,175) | 1,410 |
| Operating lease liabilities | (29) | 9 |
| Net cash used in operating activities | (24,081) | (18,757) |
| Cash flows from investing activities: | ||
| Purchases of investments | (73,898) | — |
| Proceeds from sales/maturities of investments | 65,428 | — |
| Net cash used in investing activities | $(8,470) | — |
Item 1. Financial Statements.
FAQ
- What is Jade Biosciences's operating cash flow?
- Jade Biosciences (JBIO) reported operating cash flow of -$24.08M in Q1 2026.
- How has Jade Biosciences's operating cash flow changed year-over-year?
- Jade Biosciences's operating cash flow decreased by 28.4% year-over-year, from -$18.76M to -$24.08M.
- What is the long-term trend for Jade Biosciences's operating cash flow?
- Over 4 years (2021 to 2025), Jade Biosciences's operating cash flow has grown at a 36.3% compound annual growth rate (CAGR), from -$27.4M to -$94.69M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Jade Biosciences's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude